884 related articles for article (PubMed ID: 28404866)
1. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.
Allen E; Jabouille A; Rivera LB; Lodewijckx I; Missiaen R; Steri V; Feyen K; Tawney J; Hanahan D; Michael IP; Bergers G
Sci Transl Med; 2017 Apr; 9(385):. PubMed ID: 28404866
[TBL] [Abstract][Full Text] [Related]
2. Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.
Schmittnaegel M; Rigamonti N; Kadioglu E; Cassará A; Wyser Rmili C; Kiialainen A; Kienast Y; Mueller HJ; Ooi CH; Laoui D; De Palma M
Sci Transl Med; 2017 Apr; 9(385):. PubMed ID: 28404865
[TBL] [Abstract][Full Text] [Related]
3. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
Zhang Y; Wang F; Sun HR; Huang YK; Gao JP; Huang H
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2209-2222. PubMed ID: 33891173
[TBL] [Abstract][Full Text] [Related]
4. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M
Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036
[TBL] [Abstract][Full Text] [Related]
5. Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.
Shigeta K; Datta M; Hato T; Kitahara S; Chen IX; Matsui A; Kikuchi H; Mamessier E; Aoki S; Ramjiawan RR; Ochiai H; Bardeesy N; Huang P; Cobbold M; Zhu AX; Jain RK; Duda DG
Hepatology; 2020 Apr; 71(4):1247-1261. PubMed ID: 31378984
[TBL] [Abstract][Full Text] [Related]
6. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer.
Gong X; Li X; Jiang T; Xie H; Zhu Z; Zhou F; Zhou C
J Thorac Oncol; 2017 Jul; 12(7):1085-1097. PubMed ID: 28478231
[TBL] [Abstract][Full Text] [Related]
7. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.
Black M; Barsoum IB; Truesdell P; Cotechini T; Macdonald-Goodfellow SK; Petroff M; Siemens DR; Koti M; Craig AW; Graham CH
Oncotarget; 2016 Mar; 7(9):10557-67. PubMed ID: 26859684
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
Xu C; Zhang Y; Rolfe PA; Hernández VM; Guzman W; Kradjian G; Marelli B; Qin G; Qi J; Wang H; Yu H; Tighe R; Lo KM; English JM; Radvanyi L; Lan Y
Clin Cancer Res; 2017 Oct; 23(19):5869-5880. PubMed ID: 28679778
[No Abstract] [Full Text] [Related]
9. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
[TBL] [Abstract][Full Text] [Related]
10. Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF.
Di Tacchio M; Macas J; Weissenberger J; Sommer K; Bähr O; Steinbach JP; Senft C; Seifert V; Glas M; Herrlinger U; Krex D; Meinhardt M; Weyerbrock A; Timmer M; Goldbrunner R; Deckert M; Scheel AH; Büttner R; Grauer OM; Schittenhelm J; Tabatabai G; Harter PN; Günther S; Devraj K; Plate KH; Reiss Y
Cancer Immunol Res; 2019 Dec; 7(12):1910-1927. PubMed ID: 31597643
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb.
Uehara J; Ohkuri T; Kosaka A; Ishibashi K; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Ishida-Yamamoto A; Kobayashi H
Biochem Biophys Res Commun; 2017 Aug; 490(2):521-527. PubMed ID: 28624449
[TBL] [Abstract][Full Text] [Related]
13. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.
Osada T; Patel SP; Hammond SA; Osada K; Morse MA; Lyerly HK
Cancer Immunol Immunother; 2015 Jun; 64(6):677-88. PubMed ID: 25742933
[TBL] [Abstract][Full Text] [Related]
14. Anti-VEGF/VEGFR2 Monoclonal Antibodies and their Combinations with PD-1/PD-L1 Inhibitors in Clinic.
Gao F; Yang C
Curr Cancer Drug Targets; 2020; 20(1):3-18. PubMed ID: 31729943
[TBL] [Abstract][Full Text] [Related]
15. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
16. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.
Speranza MC; Passaro C; Ricklefs F; Kasai K; Klein SR; Nakashima H; Kaufmann JK; Ahmed AK; Nowicki MO; Obi P; Bronisz A; Aguilar-Cordova E; Aguilar LK; Guzik BW; Breakefield X; Weissleder R; Freeman GJ; Reardon DA; Wen PY; Chiocca EA; Lawler SE
Neuro Oncol; 2018 Jan; 20(2):225-235. PubMed ID: 29016938
[TBL] [Abstract][Full Text] [Related]
17. Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy.
Kobold S; Grassmann S; Chaloupka M; Lampert C; Wenk S; Kraus F; Rapp M; Düwell P; Zeng Y; Schmollinger JC; Schnurr M; Endres S; Rothenfußer S
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26105028
[TBL] [Abstract][Full Text] [Related]
18. Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.
Azpilikueta A; Agorreta J; Labiano S; Pérez-Gracia JL; Sánchez-Paulete AR; Aznar MA; Ajona D; Gil-Bazo I; Larrayoz M; Teijeira A; Rodriguez-Ruiz ME; Pio R; Montuenga LM; Melero I
J Thorac Oncol; 2016 Apr; 11(4):524-36. PubMed ID: 26845193
[TBL] [Abstract][Full Text] [Related]
19. Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells.
Lai Q; Wang H; Li A; Xu Y; Tang L; Chen Q; Zhang C; Gao Y; Song J; Du Z
Oncogene; 2018 Apr; 37(17):2302-2312. PubMed ID: 29422611
[TBL] [Abstract][Full Text] [Related]
20. Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer.
Einstein DJ; McDermott DF
Clin Adv Hematol Oncol; 2017 Jun; 15(6):478-488. PubMed ID: 28749908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
